Interactions between chemokine and mu-opioid receptors: anatomical findings and electrophysiological studies in the rat periaqueductal grey.
Opioids have immunomodulatory functions and may alter susceptibility to immune disorders. Behavioral studies also indicate that chemokines, molecules expressed by immune cells, block opioid-induced analgesia in the periaqueductal grey (PAG). Bi-directional heterologous desensitization of opioid and chemokine receptors has been described in cell systems. We report the anatomical and functional interactions of chemokine receptors with the mu-opioid receptor (MOR) in the rat brain. The chemokine receptors, CXCR4 and CX3CR1, as well as their chemokine substrates, CXCL12 and CX3CL1, are widely expressed in the central nervous system (CNS). Immunohistochemical techniques were utilized to investigate MOR-CXCR4 and MOR-CX3CR1 receptor colocalization in multiple brain areas. Our results demonstrate co-expression of these receptors on individual neurons in several regions including cingulate cortex, hippocampus, and PAG, suggesting functional receptor interactions. Whole-cell patch-clamp recordings of PAG neurons in a rat brain slice preparation were used to examine morphine or chemokine (CXCL12, CX3CL1) effects alone, or in combination on neuronal membrane properties. Morphine (10 μM) hyperpolarized and reduced input resistance of PAG neurons. CXCL12 and CX3CL1 (10 nM) had no impact on either parameter. In the presence of CXCL12, morphine's electrophysiological effects were blocked in all neurons examined, whereas with CX3CL1, morphine's effects were blocked in 57% of neurons studied. The data provide electrophysiological evidence for MOR-CXCR4 and MOR-CX3CR1 heterologous desensitization in the PAG at the single-cell level. These interactions may contribute to the limited utility of opioid analgesics for inflammatory pain treatment and supports chemokines as neuromodulators.
Heinisch
Silke
S
Department of Anatomy and Cell Biology and Center for Substance Abuse Research, Temple University School of Medicine, Philadelphia, PA 19140, USA.
Palma
Jonathan
J
Kirby
Lynn G
LG
D000818:Animals; D000906:Antibodies / Q000737:chemistry / Q000276:immunology; D001923:Brain Chemistry / Q000502:physiology; D000073883:CX3C Chemokine Receptor 1; D002540:Cerebral Cortex / Q000187:drug effects / Q000378:metabolism; D018925:Chemokines / Q000502:physiology*; D055724:Electrophysiological Phenomena; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D008564:Membrane Potentials / Q000502:physiology; D008856:Microscopy, Fluorescence; D009474:Neurons / Q000502:physiology; D018408:Patch-Clamp Techniques; D010487:Periaqueductal Gray / Q000033:anatomy & histology* / Q000502:physiology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D019718:Receptors, CXCR4 / Q000378:metabolism; D019707:Receptors, Chemokine / Q000378:metabolism; D017450:Receptors, Opioid, mu / Q000502:physiology*
D000906:Antibodies; D000073883:CX3C Chemokine Receptor 1; C516305:CX3CR1 protein, rat; D018925:Chemokines; D019718:Receptors, CXCR4; D019707:Receptors, Chemokine; D017450:Receptors, Opioid, mu